Related Experiment Video
Updated: Sep 3, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults
Anthony Simone1, John Herald1, Aiyu Chen2
1Department of Cardiology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
Introduction:
Myocarditis has been reported following the second dose of COVID-19 mRNA vaccination. Whether administration of additional doses of COVID-19 vaccines further increases the risk of myocarditis is unknown.
Methods:
We included individuals who received one to three doses of BNT162b2 or mRNA-1273 mRNA vaccine between 12/14/2020 and 2/18/2022. Myocarditis within 21 days of vaccine administration was identified using electronic medical records. Incidence rate ratios were calculated by comparing the observed incidence with the expected incidence from the same population during a 365-day baseline period.
Results:
Of 3,076,660 KPSC members who received at least one dose of COVID-19 mRNA vaccines, 2,916,739 (94.5%) received at least two doses, and 1,146,254 (47.0%) received three doses. The incidence rate ratio for myocarditis was 0.86 (95% CI 0.31-1.93) for the first dose, 4.22 (95% CI 2.63-6.53) for the second dose, and 2.61 (1.13-5.29) for the third dose. Most myocarditis cases following the second and third dose occurred within seven days of vaccination.
Conclusion:
Myocarditis was a rare event observed after the second or third dose of vaccination. Most cases presented within seven days of vaccination. The incidence of myocarditis following the third dose was not significantly higher than that observed after the second dose.
Insights
COVID-19 mRNA vaccines are associated with a rare risk of myocarditis, particularly after the second dose. The risk of myocarditis after a third dose was not significantly higher than after the second dose.
Area of Science:
- Cardiology
- Vaccinology
- Public Health
Background:
- Myocarditis cases have been documented following the second dose of COVID-19 mRNA vaccines.
- The impact of additional vaccine doses on myocarditis risk remains unclear.
Purpose of the Study:
- To investigate the incidence of myocarditis following first, second, and third doses of COVID-19 mRNA vaccines (BNT162b2 and mRNA-1273).
- To compare the risk of myocarditis after the third vaccine dose versus the second dose.
Main Methods:
- Retrospective cohort study of over 3 million individuals receiving 1-3 doses of mRNA COVID-19 vaccines.
- Myocarditis cases identified within 21 days of vaccination using electronic health records.
- Incidence rate ratios calculated by comparing observed myocarditis rates to baseline rates.
Main Results:
- The incidence rate ratio for myocarditis was 0.86 (95% CI 0.31-1.93) for the first dose.
- The incidence rate ratio for myocarditis was 4.22 (95% CI 2.63-6.53) for the second dose.
- The incidence rate ratio for myocarditis was 2.61 (95% CI 1.13-5.29) for the third dose, with most cases occurring within seven days of vaccination.
Conclusions:
- Myocarditis is a rare event following mRNA COVID-19 vaccination, primarily observed after the second and third doses.
- The incidence of myocarditis after the third dose was not significantly higher than that observed after the second dose.
- Most myocarditis cases present within seven days of vaccination, suggesting a need for continued surveillance.
More Related Videos
12:24Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
05:15Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
Published on: July 27, 2022
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Myocarditis IV: Nursing Management
Pericarditis III: Medical Management
Endocarditis III: Medical Management